Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | NYSE | Healthcare | Pharmaceuticals | $805.51B | 39.8x | 0.42 | $898.89 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.6% Upside | Upgrade to Pro+ | |
| J&J | NYSE | Healthcare | Pharmaceuticals | $573.35B | 27.3x | -7.06 | $238.01 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.5% Upside | Upgrade to Pro+ | |
| AbbVie | NYSE | Healthcare | Pharmaceuticals | $364.74B | 87.4x | -70.78 | $206.22 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.4% Upside | Upgrade to Pro+ | |
| Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | $335.94B | 19.8x | 0.36 | $50.82 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.8% Upside | Upgrade to Pro+ | |
| AstraZeneca | NYSE | Healthcare | Pharmaceuticals | $312.32B | 30.6x | 0.68 | $199.65 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.1% Upside | Upgrade to Pro+ | |
| Novartis | OTC Markets | Healthcare | Pharmaceuticals | $290.24B | 21.3x | 0.96 | $156.48 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Novartis ADR | NYSE | Healthcare | Pharmaceuticals | $290.24B | 21.3x | 0.96 | $151.24 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.2% Downside | Upgrade to Pro+ | |
| Merck&Co | NYSE | Healthcare | Pharmaceuticals | $289.69B | 16.1x | 2.02 | $117.28 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13% Upside | Upgrade to Pro+ | |
| UnitedHealth | NYSE | Healthcare | Healthcare Providers & Services | $283.49B | 23.7x | -1.61 | $312.38 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.1% Upside | Upgrade to Pro+ | |
| Thermo Fisher Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | $195.93B | 29.8x | 3.99 | $527.38 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.3% Upside | Upgrade to Pro+ | |
| Amgen | NASDAQ | Healthcare | Pharmaceuticals | $186.64B | 24.2x | 0.28 | $345.77 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0% Upside | Upgrade to Pro+ | |
| Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | $176.58B | 11x | 6.03 | $39.83 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.5% Upside | Upgrade to Pro+ | |
| Abbott Labs | NYSE | Healthcare | Healthcare Equipment & Supplies | $176.38B | 27.2x | -0.53 | $101.21 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.6% Upside | Upgrade to Pro+ | |
| Gilead | NASDAQ | Healthcare | Pharmaceuticals | $172.27B | 20.3x | 0.01 | $138.57 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.7% Upside | Upgrade to Pro+ | |
| Intuitive Surgical | NASDAQ | Healthcare | Healthcare Equipment & Supplies | $166.71B | 58.7x | 2.59 | $468.89 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.8% Upside | Upgrade to Pro+ | |
| Pfizer | NYSE | Healthcare | Pharmaceuticals | $153.76B | 19.8x | -5.94 | $27.03 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1% Upside | Upgrade to Pro+ | |
| Danaher | NYSE | Healthcare | Healthcare Equipment & Supplies | $140.63B | 39.5x | -8.59 | $198.77 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.7% Upside | Upgrade to Pro+ | |
| Stryker | NYSE | Healthcare | Healthcare Equipment & Supplies | $131.52B | 40.4x | 4.97 | $343.70 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.4% Upside | Upgrade to Pro+ | |
| Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | $117.48B | 16.6x | 0.09 | $57.41 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.7% Upside | Upgrade to Pro+ | |
| GSK plc | OTC Markets | Healthcare | Pharmaceuticals | $115.96B | 15.2x | 0.12 | $29.24 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | $115.96B | 15.2x | 0.12 | $57.53 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.4% Downside | Upgrade to Pro+ | |
| Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | $115.93B | 20.2x | 0.45 | $47.70 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.6% Upside | Upgrade to Pro+ | |
| Essilor International SA | OTC Markets | Healthcare | Healthcare Equipment & Supplies | $112.15B | 41.2x | -13.96 | $120.68 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Vertex | NASDAQ | Healthcare | Pharmaceuticals | $111.82B | 28.6x | 0.03 | $439.37 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.6% Upside | Upgrade to Pro+ | |
| Medtronic | NYSE | Healthcare | Healthcare Equipment & Supplies | $111.20B | 24.2x | 2.59 | $86.58 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.8% Upside | Upgrade to Pro+ | |
| HCA | NYSE | Healthcare | Healthcare Providers & Services | $109.62B | 17.2x | 0.57 | $490.21 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11% Upside | Upgrade to Pro+ | |
| McKesson | NYSE | Healthcare | Pharmaceuticals | $105.71B | 24.8x | 0.41 | $862.87 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.9% Upside | Upgrade to Pro+ | |
| CVS Health Corp | NYSE | Healthcare | Healthcare Providers & Services | $96.17B | 54.2x | -0.91 | $75.08 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.7% Upside | Upgrade to Pro+ | |
| Boston Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | $95.50B | 33.3x | 0.59 | $64.28 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | $89.67B | 32.8x | 2.67 | $27.18 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Regeneron Pharma | NASDAQ | Healthcare | Pharmaceuticals | $76.45B | 18x | 2.1 | $744.10 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.1% Upside | Upgrade to Pro+ | |
| Cigna | NYSE | Healthcare | Healthcare Providers & Services | $70.26B | 12x | 0.15 | $267.02 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.5% Upside | Upgrade to Pro+ | |
| Elevance Health | NYSE | Healthcare | Healthcare Providers & Services | $67.72B | 12.3x | -6.64 | $308.39 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.5% Upside | Upgrade to Pro+ | |
| Hoya Corp | OTC Markets | Healthcare | Healthcare Equipment & Supplies | $63.55B | 41.2x | 1.71 | $189.39 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
| Medline | NASDAQ | Healthcare | Healthcare Equipment & Supplies | $62.62B | 30x | 0.02 | $47.77 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.3% Upside | Upgrade to Pro+ | |
| Cencora Inc | NYSE | Healthcare | Healthcare Equipment & Supplies | $61.87B | 38x | 2.05 | $317.78 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.4% Upside | Upgrade to Pro+ | |
| Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | $60.15B | 19.5x | -3.18 | $27.62 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.9% Upside | Upgrade to Pro+ | |
| UCB ADR | OTC Markets | Healthcare | Pharmaceuticals | $59.87B | 32.5x | 0.71 | $156.96 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.9% Upside | Upgrade to Pro+ | |
| Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | $56.15B | 80.2x | -1.73 | $34.52 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | $56.15B | 80.2x | -1.71 | $17.86 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.6% Upside | Upgrade to Pro+ | |
| argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $52.30B | 40x | 0.74 | $838.03 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.4% Upside | Upgrade to Pro+ | |
| Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | $50.68B | 20.1x | 1.89 | $120.38 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.7% Upside | Upgrade to Pro+ | |
| Siemens Healthineers ADR | OTC Markets | Healthcare | Healthcare Equipment & Supplies | $50.59B | 21.9x | 2.86 | $22.62 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.3% Upside | Upgrade to Pro+ | |
| Cardinal Health | NYSE | Healthcare | Pharmaceuticals | $50.06B | 30.4x | 1.04 | $212.49 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.2% Upside | Upgrade to Pro+ | |
| Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | $48.33B | 39.5x | -0.28 | $68.17 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.2% Upside | Upgrade to Pro+ | |
| CSL | OTC Markets | Healthcare | Pharmaceuticals | $47.79B | 34.9x | -0.68 | $25.41 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29% Upside | Upgrade to Pro+ | |
| Bayer AG PK | OTC Markets | Healthcare | Pharmaceuticals | $47.28B | -11.1x | 0.26 | $12.01 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.4% Upside | Upgrade to Pro+ | |
| IDEXX Labs | NASDAQ | Healthcare | Healthcare Equipment & Supplies | $46.26B | 44.3x | 1.94 | $581.33 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.8% Upside | Upgrade to Pro+ | |
| Edwards Lifesciences | NYSE | Healthcare | Healthcare Equipment & Supplies | $44.77B | 42.7x | -0.58 | $77.64 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.2% Upside | Upgrade to Pro+ | |
| Becton Dickinson | NYSE | Healthcare | Healthcare Equipment & Supplies | $44.29B | 25.4x | 8.16 | $155.36 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.4% Upside | Upgrade to Pro+ |